"Designing Growth Strategies is in our DNA"

Oncology Drugs Market Size, Share & Industry Analysis, By Drugs Class (Cytotoxic Drugs {Alkylating Agents, Antimetabolites, & Others}, Targeted Drugs {Monoclonal Antibodies & Others}, Hormonal Drugs, & Others), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, & Others), By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, & Others), By Dosage Form (Solid {Tablets & Capsules}, Liquid, & Injectable {Prefilled Syringes & Others}), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Others), and Regional Forecast, 2026-2034

Last Updated: March 09, 2026 | Format: PDF | Report ID: FBI103431

 


To get information on various segments, share your queries with us

ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year  2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 11.77% from 2026-2034
Unit Value (USD Billion)
Segmentation By Drug Class, Therapy, Indication, Dosage Form, Distribution Channel, and Region
By Drug Class
  • Cytotoxic Drugs
    • Alkylating Agents
    • Antimetabolites
    • Others
  • Targeted Drugs
    • Monoclonal Antibodies
    • Others
  • Hormonal Drugs
  • Others
By Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
By Indication
  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others
By Dosage Form
  • Solid
    • Tablets
    • Capsules
  • Liquid
  • Injectable
    • Prefilled Syringes
    • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Region
  • North America (By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • U.S. (By Drug Class)
    • Canada (By Drug Class)
  • Europe (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • U.K. (By Drug Class)
    • Germany (By Drug Class)
    • France (By Drug Class)
    • Italy (By Drug Class)
    • Spain (By Drug Class)
    • Scandinavia (By Drug Class)
    • Rest of Europe (By Drug Class)
  • Asia Pacific (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • Japan (By Drug Class)
    • China (By Drug Class)
    • India (By Drug Class)
    • Australia (By Drug Class)
    • Southeast Asia (By Drug Class)
    • Rest of Asia Pacific (By Drug Class)
  • Latin America (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • Brazil (By Drug Class)
    • Mexico (By Drug Class)
    • Rest of Latin America (By Drug Class)
  • Middle East & Africa (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • South Africa (By Drug Class)
    • GCC (By Drug Class)
    • Rest of the Middle East & Africa (By Drug Class)

 

Oncology Drugs Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 270
  • Buy Now

    (Offer valid till 31st Mar 2026)

Download Free Sample

    man icon
    Mail icon
    Captcha refresh

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Get 20% Free Customization On This Report
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports